The virus-induced protein APOBEC3G inhibits anoikis by activation of Akt kinase in pancreatic cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wu, Jia ^a   Pan, Tian Hui ^a   Xu, Song ^a   Jia, Li Tao ^a,c   Zhu, Lin Lin ^a   Mao, Jian Shan ^a   Zhu, Yong Liang ^a,b   Cai, Jian Ting ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Tongde Hospital of Zhejiang Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3G PROTEIN, HUMAN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL; ANOIKIS; BINDING SITE; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANOIKIS; APOBEC-3G DEAMINASE; BINDING SITES; CELL LINE, TUMOR; CYTIDINE DEAMINASE; ENZYME ACTIVATION; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; UP-REGULATION;

EID: 84937137587     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12230     Document Type: Article

References (49)

1. Siegel R., Naishadham D. & Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 62, 10-29 (2012
2. Michl P. & Gress T. M. Current concepts and novel targets in advanced pancreatic cancer. Gut. 60, 317-326 (2013
3. Nagaprashantha L. D., Vatsyayan R., Lelsani P. C., Awasthi S. & Singhal S. S. The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer. 128, 743-752 (2011
4. Frisch S. M. & Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124, 619-626 (1994
5. Douma S., et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 430, 1034-1039 (2004
6. Guadamillas M. C., Cerezo A. & Del Pozo M. A. Overcoming anoikis-pathways to anchorage-independent growth in cancer. J Cell Sci. 124, 3189-3197 (2011
7. Taddei M. L., Giannoni E., Fiaschi T. & Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol. 226, 380-393 (2012
8. Morris J. P. 4th., Wang S. C. & Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 10, 683-695 (2010
9. Xu J., et al. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21- activated kinase 1. Gastroenterology. 143, 199-212 (2012
10. Liu W., et al. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology. 56, 2268-2276 (2012
11. Liang Q., Xu Z., Xu R., Wu L. & Zheng S. Expression patterns of non-coding spliced transcripts from human endogenous retrovirus HERV-H elements in colon cancer. PLoS One. 7, e29950 (2012
12. Cimino-Mathews A., Sharma R. & Illei P. B. Detection of human papillomavirus in small cell carcinomas of the anus and rectum. Am J Surg Pathol. 36, 1087-1092 (2012
13. Huang J., Magnusson M., Torner A., Ye W. & Duberg A. S. Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. Br J Cancer. 109, 2917-2923 (2013
14. Wang D. S., et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 131, 461-468 (2012
15. Stoye J. P. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol. 10, 395-406 (2012
16. Young G. R., et al. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature. 491, 774-778 (2012
17. Lamprecht B., et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 16, 571-579 (2010
18. Conticello S. G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9, 229 (2008
19. Kitamura S., et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol. 19, 1005-1010 (2012
20. Chiu Y. L. & Greene W. C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol. 26, 317-353 (2008
21. Ding Q., et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 121, 4526-4536 (2011
22. Zennou V. & Bieniasz P. D. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology. 349, 31-40 (2006
23. Chaipan C., Smith J. L., Hu W. S. & Pathak V. K. APOBEC3G Restricts HIV-1 to a Greater Extent than APOBEC3F and APOBEC3DE in Human Primary CD4+ T Cells and Macrophages. J Virol. 87, 444-453 (2013
24. Kruyt F. A. & Schuringa J. J. Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochem Pharmacol. 80, 423-430 (2010
25. Zheng Y., et al. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene. 32, 4304-4312 (2013
26. Nowarski R., Britan-Rosich E., Shiloach T. & Kotler M. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol. 15, 1059-1066 (2008
27. Smith H. C. APOBEC3G: a double agent in defense. Trends Biochem Sci. 36, 239-244 (2011
28. Holden L. G., et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature. 456, 121-124 (2008
29. Li X., et al. Functional analysis of the two cytidine deaminase domains in Apobec3g. Virology. 414, 130-136 (2011
30. Jager S., et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature. 481, 371-375 (2012
31. Nowarski R., et al. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood. 120, 366-375 (2012
32. Zhong X. & Rescorla F. J. Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal. 24, 393-401 (2012
33. Mani S. A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133, 704-715 (2008
34. Simpson C. D., Anyiwe K. & Schimmer A. D. Anoikis resistance and tumor metastasis. Cancer Lett. 272, 177-185 (2008
35. Kelly P. N. & Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18, 1414-1424 (2011
36. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 19, 67-74 (2012
37. Ng K. P., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 18, 521-528 (2012
38. Wang C. & Youle R. J. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene. 31, 3177-3189 (2012
39. Szabo I., Soddemann M., Leanza L., Zoratti M. & Gulbins E. Single-point mutations of a lysine residue change function of Bax and Bcl-xL expressed in Bax- and Bak-less mouse embryonic fibroblasts: novel insights into the molecular mechanisms of Bax-induced apoptosis. Cell Death Differ. 18, 427-438 (2011
40. Galmiche A., et al. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res. 8, 1116-1125 (2010
41. Woods N. T., Yamaguchi H., Lee F. Y., Bhalla K. N. & Wang H. G. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 67, 10744-10752 (2007
42. Tait S. W. & Green D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11, 621-632 (2010
43. Sakamaki J., et al. Arginine methylation of BCL-2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt. Proc Natl Acad Sci U S A. 108, 6085-6090 (2011
44. Bai D., Ueno L. & Vogt P. K. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 125, 2863-2870 (2009
45. Mosessian S., et al. Analysis of PTEN complex assembly and identification of heterogeneous nuclear ribonucleoprotein C as a component of the PTEN-associated complex. J Biol Chem. 284, 30159-30166 (2009
46. Song M. S., Salmena L. & Pandolfi P. P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13, 283-296 (2012
47. Blanco-Aparicio C., Renner O., Leal J. F. & Carnero A. PTEN, more than the AKT pathway. Carcinogenesis. 28, 1379-1386 (2007
48. Vitolo M. I., et al. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res 69, 8275-8283 (2009
49. Zhang S. & Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 16, 4325-4330 (2010